Log in to your Inderes Free account to see all free content on this page.

Active Biotech

0.07 SEK

+7.97 %

Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+7.97 %

+1.26 %

-50.89 %

-68.61 %

-24.71 %

-43.11 %

-80.59 %

-83.86 %

-98.43 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Market cap

171.34M SEK

Turnover

1.21M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.2.

2026

Annual report '25

7.5.

2026

Interim report Q1'26

20.5.

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Press release11/25/2025, 9:00 AM

Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Regulatory press release11/25/2025, 7:30 AM

The subscription period in Active Biotech’s rights issue begins today

Press release11/24/2025, 8:30 AM

Positive preclinical tasquinimod data in myelofibrosis published in Blood Advances

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/20/2025, 2:45 PM

Active Biotech publishes information document regarding rights issue

Regulatory press release11/19/2025, 11:00 AM

Extraordinary General Meeting of Active Biotech AB

Press release11/10/2025, 8:45 AM

Redeye: Active Biotech (Q3 Review) - Rights Issue Funds 2026-2027

Regulatory press release11/6/2025, 7:30 AM

Active Biotech Interim Report Q3 2025

Press release11/3/2025, 3:30 PM

Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025

Regulatory press release10/17/2025, 6:35 PM

NOTICE OF EXTRAORDINARY GENERAL MEETING

Regulatory press release10/17/2025, 6:30 PM

Active Biotech announces a fully secured rights issue of approximately SEK 70 million

Press release9/10/2025, 11:00 AM

Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October

Press release8/25/2025, 2:40 PM

Redeye: Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal

Regulatory press release8/21/2025, 6:30 AM

INTERIM REPORT Q2 2025

Press release7/8/2025, 6:30 AM

Active Biotech provides status update of its development programs

Press release6/30/2025, 3:15 PM

Interview with investigators of laquinimod eye drop study LION now available on Active Biotech’s website

Press release6/9/2025, 2:50 PM

Results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma presented at ASCO 2025 available on Active Biotech’s website

Regulatory press release5/28/2025, 4:30 PM

Annual General Meeting of Active Biotech AB

Press release5/23/2025, 6:30 AM

Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma

Press release5/21/2025, 6:30 AM

Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe

Press release5/11/2025, 3:59 PM

Redeye: Active Biotech Q1 2025 - Important results with laquinimod

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.